Wall Street Expects These Stocks to Soar 175% and 545%. Should You Buy?
Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. I'm talking about (NASDAQ: NVAX) and Ocugen (NASDAQ: OCGN). Both companies raced to bring a coronavirus vaccine to market.
As it turns out, Novavax reached commercialization -- but later than today's market leaders, Pfizer and Moderna. And Ocugen dropped its flagship vaccine program and replaced it with earlier-stage work on inhaled-vaccine candidates.
Both stocks are falling in the double digits this year, and that's after poor performance last year. But could they be heading for a major rebound as Wall Street predicts? And should you get in on these recovery stories?
Source Fool.com
Novavax Inc. Aktie
Leichtes Buy-Überwiegen bei Novavax Inc. im Vergleich zu Sell-Einschätzungen.
Das von der Community festgelegte Kursziel für Novavax Inc. von 22 € würde den aktuellen Kurs von 10.38 € mehr als verdoppeln.
